Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2020 · 10-Q
Revenue$8.25M$8.25M+6.8% vs Q3 2019 Net Income-$6.23M-$6.23MN/M vs Q3 2019 EPS Diluted-$1.54-$1.54N/M vs Q3 2019 Gross Profit$3,054,000+5.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,722,000N/M Free Cash Flowderived-$6,084,000N/M Margins · derivedGross margin37.0%−0.4 pt vs Q3 2019
Operating margin-72.8%+19.5 pt vs Q3 2019
Net margin-75.6%+20.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Jan 20, 2021 · 112 d after period end